Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

By afschroeder • May 10, 2026

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 May 9. doi: 10.1007/s13555-026-01774-2. Epub ahead of print. PMID: 42105056.

Tags: Dermatology, Investigator Global Assessment modified 2011 of the scalp (IGA mod 2011 [scalp]) score, Obesity, Olive View DoM, plaque psoriasis, Psoriasis Scalp Severity Index (PSSI), Publications, scalp psoriasis, tildrakizumab

Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis

Bchiri S, Bahrini K, Teles RMB, Alaya AB, Kamel HE, West J, Rategh K, Bouzekri A, Bousalem E, Ouni R, Fassatoui M, Mardassi H, Dekhil[...]

Combined High Dose-Rate Interstitial Brachytherapy and Stereotactic Body Radiotherapy in Unresectable Primary Vaginal Melanoma: A Case Report

Ariani RT, Khan S, Venkat P. Combined High Dose-Rate Interstitial Brachytherapy and Stereotactic Body Radiotherapy in Unresectable Primary Vaginal Melanoma: A Case Report. Cureus. 2026[...]

Development of a Core Outcome Domain Set for Facial Aging

Dirr MA, Ahmed A, Schlessinger DI, Lazaro-Camp V, Smith S, Gullapalli T, Dragovic D, Chang J, Zhang E, Alam M; Facial Aging Core Outcome Domain[...]